AVI-3307 / Dx&Vx - LARVOL DELTA

Dx&Vx, Acquisition of New Drug Development Company… Rapid Expansion of Pipeline [Google translation] (Medipana) - "Dx&Vx, a bio-healthcare company, is moving forward with the acquisition of new drug development company 'Avixgen'. Through this merger, Dx&Vx plans to integrate Avixgen's specialized research and development capabilities and strengthen the company's ophthalmology and inflammatory disease new drug development pipeline....The merger date is December 17, and the expected listing date for new shares is January 6, 2025."

M&A • Age-related Macular Degeneration • Immunology • Ophthalmology • Wet Age-related Macular Degeneration